ArticleChinese medical journal2026

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Wei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.